Aaron Rosenberg - 06 Mar 2026 Form 4 Insider Report for BeOne Medicines Ltd. (ONC)

Role
Chief Financial Officer
Signature
/s/ Qing Nian, as Attorney-in-Fact
Issuer symbol
ONC
Transactions as of
06 Mar 2026
Net transactions value
$0
Form type
4
Filing time
10 Mar 2026, 20:11:32 UTC
Previous filing
05 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rosenberg Aaron Chief Financial Officer C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, SWITZERLAND /s/ Qing Nian, as Attorney-in-Fact 10 Mar 2026 0002031182

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONC Ordinary Shares Award +79,014 +37% $0.000000* 294,346 06 Mar 2026 Direct F1
transaction ONC Ordinary Shares Award +40,573 +14% $0.000000* 334,919 06 Mar 2026 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the total number of ordinary shares underlying the performance share units earned by Reporting Person. The earned performance share units will vest in 2027, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Unvested securities are subject to accelerated vesting upon certain termination events.
F2 Represents the total number of ordinary shares underlying the performance share units earned by Reporting Person. The earned performance share units will vest in 2028, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Unvested securities are subject to accelerated vesting upon certain termination events.